$98,144,230

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

to MEDICINES COMPANY, THE

biotechactiveONGOING · MOD OF 2016 CONTRACT

WORK BEGAN2016-09-15·LATEST ACTION2026-02-20·SOURCEUSASPENDING·SOURCE IDCONT_AWD_HHSO100201600026C_7505_-NONE-_-NONE-

Award description

THE MEDICINE COMPANY - ADVANCE THE DEVELOPMENT OF A PORTFOLIO OF ANTI-INFECTIVE PROGRAMS. IGF::OT::IGF

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Supports The Medicines Company's development of anti-infective drug programs under a long-running HHS preparedness contract that began in 2016.

Sub-sectors

anti-infective-developmentpharmaceutical-r&dhhs-aspr-medical-countermeasures

Why this matters

Strengthens U.S. capacity to develop medical countermeasures against infectious disease threats, critical for pandemic and biodefense preparedness.

Supply-chain signal

Sustains domestic pharmaceutical R&D capability and manufacturing partnerships for infectious disease treatments, reducing reliance on foreign sources.

U.S.–China competition angle

Advances U.S. pharmaceutical innovation in antibiotics and antivirals where China has gained ground in active pharmaceutical ingredient production.

Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-29. Cost: $0.003065.

Period of performance

Start

2016-09-15

End

2030-09-30

Status

activein 1539 days

Recipient

MEDICINES COMPANY, THE

UEI ZCK2MH2VMA26

View full profile →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_HHSO100201600026C_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.